Valeant Pharmaceuticals (VRX) Looking Past Allergan - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Valeant Pharma (VRX) Will Review Allergan/Actavis Deal; Can't Justify Paying $219/Share
November 17, 2014 9:31 AM ESTValeant Pharma (NYSE: VRX) commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan... More
Valeant Pharma (VRX) Falls as Allergan Goes with Actavis Deal
November 17, 2014 9:22 AM ESTValeant Pharma (NYSE: VRX) is trading down 1.3% early Monday after hostile-takeover target Allergan (NYSE: AGN) agreed to a $66 billion merger deal with Actavis (NYSE: ACT) instead.
... More